Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, enabling the company to commence U.S. manufacturing of its Alpha DaRT technology by 2026. The strong cash position of the company supports its ongoing developments, which position it favorably to address unmet needs in the oncology sector. Despite a reported net loss of $11.7 million, which is higher than prior estimates, the development advances and potential therapeutic applications of Alpha DaRT contribute to a positive future outlook for the company.

Bears say

Alpha Tau Medical Ltd reported a net loss of $11.7 million in the third quarter of 2025, highlighting financial challenges as the company advances its clinical-stage oncology therapeutics. The company faces significant risks related to the potential failure of its AlphaDaRT technology in clinical trials, the inability to secure regulatory approval in the U.S., and challenges in achieving market success, including competition and market size limitations. Additionally, concerns regarding potential dilution further exacerbate the negative outlook on the stock, indicating substantial uncertainties in the company's future financial performance.

DRTS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 2 analysts, DRTS has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.